Andrew Baum
Stock Analyst at Citigroup
(2.88)
# 1,346
Out of 5,182 analysts
67
Total ratings
76.74%
Success rate
15%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $53 → $60 | $57.78 | +3.84% | 15 | Jan 27, 2026 | |
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $26.79 | -2.95% | 11 | Aug 6, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $110.23 | +4.33% | 13 | Feb 5, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $49.65 | -19.44% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $197.38 | +8.93% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $868.27 | +3.08% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $3.30 | +203.03% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $54.22 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Jan 27, 2026
Maintains: Neutral
Price Target: $53 → $60
Current: $57.78
Upside: +3.84%
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $26.79
Upside: -2.95%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $110.23
Upside: +4.33%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $49.65
Upside: -19.44%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $197.38
Upside: +8.93%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $868.27
Upside: +3.08%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $3.30
Upside: +203.03%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $54.22
Upside: -